JBI-1527

JBI-1527 is an **oral small molecule PD-L1 inhibitor** being developed by **Jubilant Therapeutics** for oncology indications. The compound is designed to bind **programmed death-ligand 1** and induce **PD-L1 dimerization**, thereby disrupting PD-1 and CD80 related immune checkpoint signaling and reversing PD-L1-mediated suppression of T-cell activation. Preclinical data described antitumor activity and cytokine modulation comparable to checkpoint antibody benchmarks such as pembrolizumab and atezolizumab in experimental systems, supporting its development as a **checkpoint inhibitor immunotherapy** for PD-L1-expressing cancers including melanoma, non-small cell lung cancer, and breast cancer.